Literature DB >> 23860224

High-throughput screening normalized to biological response: application to antiviral drug discovery.

Dhara A Patel1, Anand C Patel, William C Nolan, Guangming Huang, Arthur G Romero, Nichole Charlton, Eugene Agapov, Yong Zhang, Michael J Holtzman.   

Abstract

The process of conducting cell-based phenotypic screens can result in data sets from small libraries or portions of large libraries, making accurate hit picking from multiple data sets important for efficient drug discovery. Here, we describe a screen design and data analysis approach that allow for normalization not only between quadrants and plates but also between screens or batches in a robust, quantitative fashion, enabling hit selection from multiple data sets. We independently screened the MicroSource Spectrum and NCI Diversity Set II libraries using a cell-based phenotypic high-throughput screening (HTS) assay that uses an interferon-stimulated response element (ISRE)-driven luciferase-reporter assay to identify interferon (IFN) signal enhancers. Inclusion of a per-plate, per-quadrant IFN dose-response standard curve enabled conversion of ISRE activity to effective IFN concentrations. We identified 45 hits based on a combined z score ≥2.5 from the two libraries, and 25 of 35 available hits were validated in a compound concentration-response assay when tested using fresh compound. The results provide a basis for further analysis of chemical structure in relation to biological function. Together, the results establish an HTS method that can be extended to screening for any class of compounds that influence a quantifiable biological response for which a standard is available.

Entities:  

Keywords:  cell-based assay; interferon signal enhancer; phenotypic drug discovery; quantitative HTS; statin

Mesh:

Substances:

Year:  2013        PMID: 23860224      PMCID: PMC3867592          DOI: 10.1177/1087057113496848

Source DB:  PubMed          Journal:  J Biomol Screen        ISSN: 1087-0571


  30 in total

1.  Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries.

Authors:  James Inglese; Douglas S Auld; Ajit Jadhav; Ronald L Johnson; Anton Simeonov; Adam Yasgar; Wei Zheng; Christopher P Austin
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-24       Impact factor: 11.205

2.  Blocking airway mucous cell metaplasia by inhibiting EGFR antiapoptosis and IL-13 transdifferentiation signals.

Authors:  Jeffrey W Tyner; Edy Y Kim; Kyotaro Ide; Mark R Pelletier; William T Roswit; Jeffrey D Morton; John T Battaile; Anand C Patel; G Alexander Patterson; Mario Castro; Melanie S Spoor; Yingjian You; Steven L Brody; Michael J Holtzman
Journal:  J Clin Invest       Date:  2006-02       Impact factor: 14.808

3.  Different anti-HCV profiles of statins and their potential for combination therapy with interferon.

Authors:  Masanori Ikeda; Ken-ichi Abe; Masashi Yamada; Hiromichi Dansako; Kazuhito Naka; Nobuyuki Kato
Journal:  Hepatology       Date:  2006-07       Impact factor: 17.425

4.  Modification of the Stat1 SH2 domain broadly improves interferon efficacy in proportion to p300/CREB-binding protein coactivator recruitment.

Authors:  Yong Zhang; Kazutaka Takami; Mindy S Lo; Guangming Huang; Qing Yu; William T Roswit; Michael J Holtzman
Journal:  J Biol Chem       Date:  2005-08-17       Impact factor: 5.157

5.  Bioconductor: open software development for computational biology and bioinformatics.

Authors:  Robert C Gentleman; Vincent J Carey; Douglas M Bates; Ben Bolstad; Marcel Dettling; Sandrine Dudoit; Byron Ellis; Laurent Gautier; Yongchao Ge; Jeff Gentry; Kurt Hornik; Torsten Hothorn; Wolfgang Huber; Stefano Iacus; Rafael Irizarry; Friedrich Leisch; Cheng Li; Martin Maechler; Anthony J Rossini; Gunther Sawitzki; Colin Smith; Gordon Smyth; Luke Tierney; Jean Y H Yang; Jianhua Zhang
Journal:  Genome Biol       Date:  2004-09-15       Impact factor: 13.583

6.  An analysis of normalization methods for Drosophila RNAi genomic screens and development of a robust validation scheme.

Authors:  Amy M Wiles; Dashnamoorthy Ravi; Selvaraj Bhavani; Alexander J R Bishop
Journal:  J Biomol Screen       Date:  2008-08-27

7.  Analysis of cell-based RNAi screens.

Authors:  Michael Boutros; Lígia P Brás; Wolfgang Huber
Journal:  Genome Biol       Date:  2006       Impact factor: 13.583

8.  Compound cytotoxicity profiling using quantitative high-throughput screening.

Authors:  Menghang Xia; Ruili Huang; Kristine L Witt; Noel Southall; Jennifer Fostel; Ming-Hsuang Cho; Ajit Jadhav; Cynthia S Smith; James Inglese; Christopher J Portier; Raymond R Tice; Christopher P Austin
Journal:  Environ Health Perspect       Date:  2008-03       Impact factor: 9.031

9.  Detecting outliers when fitting data with nonlinear regression - a new method based on robust nonlinear regression and the false discovery rate.

Authors:  Harvey J Motulsky; Ronald E Brown
Journal:  BMC Bioinformatics       Date:  2006-03-09       Impact factor: 3.169

10.  Statins inhibit HIV-1 infection by down-regulating Rho activity.

Authors:  Gustavo del Real; Sonia Jiménez-Baranda; Emilia Mira; Rosa Ana Lacalle; Pilar Lucas; Concepción Gómez-Moutón; Marta Alegret; Jose María Peña; Manuel Rodríguez-Zapata; Melchor Alvarez-Mon; Carlos Martínez-A; Santos Mañes
Journal:  J Exp Med       Date:  2004-08-16       Impact factor: 14.307

View more
  9 in total

1.  Respiratory Enterovirus (like Parainfluenza Virus) Can Cause Chronic Lung Disease if Protection by Airway Epithelial STAT1 Is Lost.

Authors:  Yong Zhang; Dailing Mao; Shamus P Keeler; Xinyu Wang; Kangyun Wu; Benjamin J Gerovac; Laurie L Shornick; Eugene V Agapov; Michael J Holtzman
Journal:  J Immunol       Date:  2019-02-25       Impact factor: 5.422

Review 2.  The role of airway epithelial cells and innate immune cells in chronic respiratory disease.

Authors:  Michael J Holtzman; Derek E Byers; Jennifer Alexander-Brett; Xinyu Wang
Journal:  Nat Rev Immunol       Date:  2014-09-19       Impact factor: 53.106

Review 3.  Linking acute infection to chronic lung disease. The role of IL-33-expressing epithelial progenitor cells.

Authors:  Michael J Holtzman; Derek E Byers; Jennifer-Alexander Brett; Anand C Patel; Eugene Agapov; Xiaohua Jin; Kangyun Wu
Journal:  Ann Am Thorac Soc       Date:  2014-12

4.  Interferon response and respiratory virus control are preserved in bronchial epithelial cells in asthma.

Authors:  Dhara A Patel; Yingjian You; Guangming Huang; Derek E Byers; Hyun Jik Kim; Eugene Agapov; Martin L Moore; R Stokes Peebles; Mario Castro; Kaharu Sumino; Adrian Shifren; Steven L Brody; Michael J Holtzman
Journal:  J Allergy Clin Immunol       Date:  2014-09-09       Impact factor: 10.793

5.  New activities for old antibiotics.

Authors:  Jeffrey I Cohen
Journal:  Nat Microbiol       Date:  2018-05       Impact factor: 17.745

6.  STAT1 modification improves therapeutic effects of interferons on lung cancer cells.

Authors:  Junjie Chen; Jialu Zhao; Lefu Chen; Nian Dong; Zhaojian Ying; Zhenzhen Cai; Dongxiang Ji; Yong Zhang; Li Dong; Yuping Li; Lei Jiang; Michael J Holtzman; Chengshui Chen
Journal:  J Transl Med       Date:  2015-09-08       Impact factor: 5.531

7.  PARP9-DTX3L ubiquitin ligase targets host histone H2BJ and viral 3C protease to enhance interferon signaling and control viral infection.

Authors:  Yong Zhang; Dailing Mao; William T Roswit; Xiaohua Jin; Anand C Patel; Dhara A Patel; Eugene Agapov; Zhepeng Wang; Rose M Tidwell; Jeffrey J Atkinson; Guangming Huang; Ronald McCarthy; Jinsheng Yu; Nadezhda E Yun; Slobodan Paessler; T Glen Lawson; Natalie S Omattage; Tom J Brett; Michael J Holtzman
Journal:  Nat Immunol       Date:  2015-10-19       Impact factor: 25.606

Review 8.  Interferon-inducer antivirals: Potential candidates to combat COVID-19.

Authors:  Ashkan Bagheri; Seyed Mohammad Iman Moezzi; Pouria Mosaddeghi; Sadra Nadimi Parashkouhi; Seyed Mostafa Fazel Hoseini; Fatemeh Badakhshan; Manica Negahdaripour
Journal:  Int Immunopharmacol       Date:  2020-12-01       Impact factor: 5.714

9.  Identification of Compounds That Prolong Type I Interferon Signaling as Potential Vaccine Adjuvants.

Authors:  Nikunj M Shukla; Kei-Ichiro Arimoto; Shiyin Yao; Jun-Bao Fan; Yue Zhang; Fumi Sato-Kaneko; Fitzgerald S Lao; Tadashi Hosoya; Karen Messer; Minya Pu; Howard B Cottam; Dennis A Carson; Tomoko Hayashi; Dong-Er Zhang; Maripat Corr
Journal:  SLAS Discov       Date:  2018-05-11       Impact factor: 3.341

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.